Rethinking phase 2 trials in amyotrophic lateral sclerosis.

Area of Science:

• Neurology
• Clinical Trial Design
• Drug Development

Background:

• Amyotrophic lateral sclerosis (ALS) research has a history of therapies failing in phase 3 trials after promising phase 2 results.
• Current phase 2 trial durations (e.g., 6 months) and outcome measures may be insufficient for ALS, a progressive neurodegenerative disease.

Purpose of the Study:

• To highlight critical issues in phase 2 clinical trial design for amyotrophic lateral sclerosis.
• To advocate for improved methodologies to ensure reliable data for phase 3 trial prioritization and to prevent false hope.

Main Methods:

• Critical review of historical trends in ALS clinical trial phases.
• Analysis of limitations in current phase 2 study designs, including duration, outcome measures, and data imputation strategies.
• Exploration of alternative surrogate markers for early efficacy assessment.

Main Results:

• Phase 2 studies in ALS are often too short and rely on outcome measures that are not sensitive enough to detect meaningful change.
• Statistical challenges, such as multiplicity and inappropriate missing data imputation, can compromise data integrity.
• Neurofilament light chain reduction shows potential as a surrogate marker for phase 2 go/no-go decisions.

Conclusions:

• Over-interpretation of phase 2 data and optimistic reporting of exploratory analyses in ALS trials must be avoided.
• Enhanced phase 2 trial design, incorporating appropriate statistical methods and validated surrogate markers, is essential for efficient drug development.
• Prioritizing robust phase 2 designs will optimize resource allocation for phase 3 trials and minimize harm to patients with ALS.